RxDoctor Payments Data

Patrick Murphy, MD

Family Medicine · Mobile, ALNPI 1316384936

Payments from drug & device makers

$13,208in general payments, 2019–2025

Across 922 payments — averaging $14.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • Amgen$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$966
  • AstraZeneca$724
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$13,174100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,208 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$204,857
Medicare patients
240
Services billed
8,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide179$195,607
MounjaroTirzepatide86$96,570
EliquisApixaban86$78,532
RybelsusSemaglutide51$74,804
JardianceEmpagliflozin69$58,846
LinzessLinaclotide52$43,394
JanuviaSitagliptin Phosphate34$39,199
XareltoRivaroxaban34$24,067
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$23,295
KerendiaFinerenone13$22,786
FarxigaDapagliflozin Propanediol22$21,851
UbrelvyUbrogepant13$17,463
GemtesaVibegron16$16,839
TrulancePlecanatide13$16,234
Repatha SureclickEvolocumab16$12,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,398$270,412230 claims
Lilly USA, LLCMounjaro$611$96,57086 claims
PfizerEliquis$544$78,53286 claims
AbbVieLinzess, Ubrelvy, Synthroid$2,664$63,100100 claims
Boehringer IngelheimJardiance$120$58,84669 claims
MerckJanuvia, Janumet$106$47,41248 claims
GSKTrelegy Ellipta, Anoro Ellipta$328$30,10234 claims
Johnson & JohnsonXarelto$966$24,06734 claims
BayerKerendia$688$22,78613 claims
AstraZenecaFarxiga$724$21,85122 claims
Sumitomo Pharma America, Inc.Gemtesa$254$16,83916 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,091$16,23413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →